You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
16 search results for: disease modification
Podcast
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and DiseaseModification in AD
Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and diseasemodification may impact disease course.
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Amy Paller discusses the benefits of early intervention for children with AD and the potential for diseasemodification.
Early Intervention and the Potential for DiseaseModification in Children With AD
Dermatology
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Amy Paller discussing the benefits of early intervention for children with AD and the potential for diseasemodification. Dr. Paller also reviews available data investigating the impacts of therapies for AD on the disease itself and on associated comorbidities.
In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of diseasemodification and how early intervention might be disease modifying in AD.
Early Intervention and the Potential For DiseaseModification in AD
Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson discusses key considerations for diseasemodification and the importance of early intervention in treating patients with AD.
Early Intervention and DiseaseModification in AD: Can We Change the Course of the Disease?
Dermatology
This video presentation of the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands features Dr. Stephan Weidinger, Dr. Eric Simpson, and Dr. Marjolein de Bruin-Weller. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating patients with AD early in the disease course, and the emerging real-world data on the use of advanced systemic therapies for patients with AD.
Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how diseasemodification in AD can impact the course of the disease and its associated comorbidities.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.